237 results about "Rectal administration" patented technology

This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2_τ receptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2_τ receptors and inhibit P2_τ receptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.

The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.

A Chinese medicine for treating irritable bowel syndrome (IBS) is prepared from 6 Chinese-medicinal materials including bupleurum root, white peony root, Chuan-xiong rhizome, liquorice root, etc. It may be particles, capsules, tablets, oral liquid injection, etc.

One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that estrogens can be administered using non-invasive modes of administration, e.g. oral or rectal administration. Other aspects of the present invention relate to a suppository for use in newborn infants comprising at least 1 μg of estrogen and to an oral applicator comprising a container holding an aqueous liquid containing micronised estetrol and a metering dispenser for metering the liquid into the oral cavity of a newborn infant.

Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft or hard shell capsules (e.g. soft gelatin capsules), suspensions or solutions. The composition can also be formulated as a suppository or enema or rectal administration. The compositions further comprise a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients. Suitable excipients include diluents, binders, plasticizers, lubricants, disintegrants, colorants, stabilizers, surfactants, and combinations thereof. The fatty acid salts, alkyl sulate salts, aryl sulfate salts or alkyl aryl sulfonate salts can be co-mixed or co-melted with one or more fatty acids to make more hydrophobic compositions, which may result in less staining formulations. The compositions can be formulated for immediate release, controlled release such as extended release, delayed release, and pulsatile release, or combinations thereof. In one embodiment, the derivative of methylene blue is methylene dodecylsulfate.

The invention relates to a formula of a sartan compound or a pharmaceutically acceptable salt thereof and a calcium channel blocker or a pharmaceutically acceptable salt, which belong to the technical field of medicine. The formula comprises the following components by weight proportion: 5-200 parts of [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and a carboxylic acid compound and salt thereof and 0.5-60 parts of a calcium ion retarder; the preferable scheme is 20-100 parts of the [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and the carboxylic acid compound and the salt thereof and 1-30 parts of the calcium ion retarder; the administration forms can be one of the following forms such as oral administration, inhalation, subcutaneous administration, sublingual administration, intramuscular administration, intravenous administration, transdermal administration, local administration or rectal administration. In the formula of the invention, an antihypertensive I and the calcium channel blocker or the pharmaceutically acceptable salt are studied; thus a preparation with a new formula for treating hypertension is provided. The preparation is characterized by low dosage, obvious blood pressure lowering effect and little adverse reaction.

The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally.

A method of contraception in mammalian females, which method comprises the parenteral or rectal administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1)

in which R₁, R₂, R₃, R₄ independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R₅, R₆, R₇ is a hydroxyl group; and no more than 3 of R₁, R₂, R₃, R₄ are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a drug delivery system for parenteral or rectal administration that contains the aforementioned estrogenic component and a progestogenic component, said drug delivery system being selected from the group consisting of suppositories, systems for intravaginal delivery, inhalers, nasal sprays and transdermal delivery systems.

The present invention relates to compounds of Formula I and Formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of Formula I and Formula II; and formulated to treat an underlying etiology by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and/or proctitis.

The invention relates to a Chinese medicine preparation for treating chronic prostatitis, which is characterized by comprising the following raw medicines: radix rehmanniae preparata, cynomorium songaricum rupr, radix astragali, rhizoma corydalis, herba epimedii, dodder, herba ecliptae, schisandra chinensis, hedyotis diffusa, safflower, radix polygoni multiflori preparata, fructus ligustri lucidi, salvia miltiorrhiza, radix paeoniae alba, myrrh, prunella vulgaris, fructus cnidii, herba patriniae, scutellaria baicalensis georgi, angelica and cortex moutan. In the invention, Chinese herbal medicines for promoting blood circulation and removing blood stasis are adopted, the permeability of capillaries can be improved, inflammation reaction can be alleviated, the extinction and the absorption of inflammation focus can be promoted, the metabolism of connective tissues can be improved, the transformation and the absorption of hyperplastic lesions can be promoted, and atrophic connective tissues can recover. When the Chinese medicine preparation for treating chronic prostatitis is applied through rectums, the medicines can be absorbed in the rectums, enema or suppository enables the medicines to be absorbed through rectum mucosa to directly reach affected parts; and the Chinese medicine preparation can reach higher consistency in diseased prostate and has the advantages of ideal treating effect, low price and simple, convenient and practical preparation method.

The invention relates to a preparation of anemoside B4 for rectal mucosal administration, comprising anemoside B4 and a pharmaceutically acceptable matrix; the preparation herein is selected from oneor two of rectal gel and rectal suppository. The invention also specifically provides rectal gel of anemoside B4, rectal suppository of anemoside B4, and their preparation methods. The preparation ofanemoside B4 for rectal mucosal administration provided herein requires less dosage than oral administration and has better effect under the same the dosage.

the invention disclose a carrying suppository for cavity/canal drug administration, and includes suppository with cartilage used for vagina, rectum, nasal cavity drug administration, and novel suppository fit for rectum drug administration and special mold caddy for molding, packing, vivo imbedding. Wherein the suppository with cartilage is comprised by suppository core 1, pull wire 2, drug-containing carrier stroma and adhesive agent and/or developing agent; The rectum drug administration suppository is comprised by drug-containing carrier stroma, isolated layer, and adhesion coat; The special mold caddy is comprised by hollow suppository push rod and mainbody mold, wherein the mainbody mold includes case cap 5, upper cavity mold 6 in the case, lower mold 7 connected together with the case, wherein the upper mold can be integrated or two-body, i.e. a central mold 8 is added. By using the provided suppository, focus can fully contact with the drug, and the drug will not flow, and has longer active time and good positioning property, so that the suppository can realize drug administration against focus local.

The invention discloses a Qingkailing suppository, relates to a Chinese medicine compound preparation, the raw materials of which mainly come from plants and animals, in particular to a novel formulation of Qingkailing preparation. The Qingkailing suppository provided by the invention for supplying rectum with medicine adopts the following components of cholic acid, hyodeoxycholic acid, baicalin, buffalo horn, the hydrolysate of mother-of-pearl, gardenia, banlangen, the water purified extract of honeysuckle as Qingkailing combination. The suppository which is 1-3g weight is made from the raw materials and supplementary materials with the following weight proportions of 8-13 proportions of Qingkailing combination, 5-50 proportions of suppository base, 0.1-5 proportions of surfactant, 0.05-3 proportions of sorbefacient, and 0-3 proportions of additional agent. The Qingkailing suppository of the invention not only can compensate the defects that the oral taking preparation is slow to take effect and injection preparation has great toxicity, but also can prolong the duration of the medicine, provides a wider selection range for clinics and sufferers, has simple production technology, is suitable for industrialized batch production, and is suitable to be taken by infants.

The invention relates to a rectal administration composition containing tamsulosin, which comprises effective quantities of tamsulosin or pharmaceutically acceptable salts or derivatives thereof, solubilizer and sorbefacient, wherein the effective quantity of tamsulosin or pharmaceutically acceptable salts or derivatives thereof is metered according to the equivalence tamsulosin hydrochloride; the content of the tamsulosin or pharmaceutically acceptable salts or derivatives thereof is equivalent to 0.025-1.6 mg of tamsulosin hydrochloride; and the preparation per unit weighs 0.8-4 g. The rectal administration composition containing tamsulosin can overcome the defects of poor curative effect and great toxic or side effect in oral administration and systemic injection administration, and the defects of great side effect and poor patient dependence in partial injection administration, and can prolong the duration of drug actions, thereby providing a better treatment means for medical care personnel and patients. The production technology is simple and suitable for industrial mass production.

Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.

The Chinese medicine enema for treating acute pancreatitis consists of rhubarb decoction and Glauber salt in certain weight ratio. It is rectum administrated to reach blood medicine concentration the same as that of vein administration but no influence of digestive enzyme and gastric acid. The medicine may be used to combine with Western medicine in treating acute pancreatitis to reach high curative rate.

The invention relates to application of dragon blood and dragon blood extract, which belongs to the field of Chinese medicaments. In particular, the invention relates to the application of dragon blood raw medicinal materials, dragon blood total phenols and dragon blood total flavonoids in preparing medicaments for preventing or treating radiation damage. In order to achieve the application of the invention, the application of the dragon blood or the dragon blood extract via or not via gastrointestinal tract includes but is not limited to oral, subcutaneous, intramuscular, intravenous, transdermal, nasal and rectal administration. Pharmaceutical compositions prepared from the dragon blood or the dragon blood extract and medically acceptable pharmaceutical excipient include but are not limited to various types of tablets, capsules, dropping pills, soft capsules, oral solution, pills, powder, granules, lozenges, decoction paste, syrup, liquid extract agent, extract agents, injections, as well as other clinically appropriate dosage forms. A preparation contains necessary additives, and the additives include but are not limited to fillers, wetting agents, adhesives, disintegrants, lubricants or pH regulators.

The invention discloses a rectal drug delivery device for gastroenterology with an electric adjustment function, which comprises a pressure pad, a pressure rod, a pressure rod positioning sleeve, a handle, a drug cartridge, an inner cavity, a liquid separator, an injection needle, and an enema tube , a rectal drug delivery device for gastroenterology with electric adjustment function of the present invention, when in use, the worm gear of the ring motor drives the rack to move back and forth, so that the pull bar connected to the rack pulls the ball valve to rotate along the ball valve shaft pin, and the two ends The return spring is tensioned to keep the through hole of the ball valve in an upward damping state. When the motor is started, the through hole of the ball valve becomes horizontal and the channel is connected; through the cooperation of the electric control valve and the liquid dispenser, the The drug delivery device can be easily controlled to inject with a needle or an enema tube, and the switch is convenient and quick, reducing the time for changing tools and working heads.